Barrow Neurological Institute is increasing the number of clinical trials for patients at its Muhammad Ali Parkinson Center in Phoenix. Dr. Holly Shill, the center’s director, says it’s important research studies are open to patients at all stages of the disease.
“We would like to see clinical trials for newly diagnosed people with therapies that might potentially slow progression and then as the disease progresses and becomes more complicated, we would develop therapies and research studies that address those unmet needs,” Shill said.
Shill says she hopes to double the number of patients in studies aimed at slowing the progression of the disease. That could mean several hundred patients would be part of the trials.
Parkinson’s disease is characterized by tremors and restricted movement. The center has more funding now for studies and outreach.
